Multiplex RT-qPCR for Simultaneous Detection of Canine Distemper Virus, Canine Parvovirus Type 2, and Canine Adenovirus Type 2 in Clinical Samples

Introduction

Canine distemper virus (CDV), canine parvovirus type 2 (CPV-2), and canine adenovirus type 2 (CAV-2) are among the most clinically significant viral pathogens affecting domestic dogs worldwide [1, 2, 3]. CDV, a morbillivirus within the family Paramyxoviridae, causes a multisystemic disease affecting the respiratory, gastrointestinal, and central nervous systems [4, 5]. CPV-2, a protoparvovirus (family Parvoviridae), is the primary etiologic agent of hemorrhagic gastroenteritis and lymphopenia in puppies [6, 7, 8]. CAV-2, a mastadenovirus (family Adenoviridae), is a major contributor to the canine infectious respiratory disease complex (CIRDC) and can also cause enteric signs [9, 10]. Co-infections with these viruses are frequently documented in shelter populations and in dogs with incomplete vaccination histories [11, 12, 13]. Rapid and accurate differential diagnosis is essential for appropriate clinical management, outbreak control, and epidemiological surveillance [14, 15].

Conventional single-target PCR or RT-PCR assays require separate reactions for each pathogen, consuming time, reagents, and sample volume [16, 17]. Multiplex real-time reverse transcription quantitative PCR (RT-qPCR) offers a solution by enabling simultaneous amplification and detection of multiple targets in a single reaction well [18, 19]. This article describes the development, analytical validation, and field application of a triplex RT-qPCR assay for the simultaneous detection of CDV, CPV-2, and CAV-2 from nasal swabs and fecal samples. The assay design, primer and probe selection, sensitivity and specificity parameters, cross-reactivity testing, and comparison with single-target PCR are discussed in detail.

Primer and Probe Design

The selection of conserved genomic regions is critical for robust multiplex assay performance [20, 21]. For CDV, the nucleoprotein (N) gene is a preferred target due to its high conservation among circulating strains [22, 23]. For CPV-2, the VP2 capsid gene is commonly targeted because it contains both conserved and variable regions that allow detection of all antigenic variants (CPV-2a, CPV-2b, CPV-2c) [24, 25]. For CAV-2, the hexon gene provides a suitable target with adequate sequence conservation across field isolates [26, 27].

Primer and probe sets must be designed to avoid significant secondary structure and to have compatible melting temperatures (Tm) within a narrow range (58-62 degrees Celsius) to ensure uniform amplification efficiency in a multiplex format [28, 29]. Hydrolysis probes (TaqMan style) labeled with distinct fluorophores (e.g., FAM, VIC, Cy5) allow discrimination of each amplicon in the same channel [30, 31]. Table 1 summarizes representative primer and probe sequences for each target.

Table 1. Oligonucleotide sequences for multiplex RT-qPCR targeting CDV, CPV-2, and CAV-2.

Note: Sequences are illustrative and derived from conserved regions described in the literature [1, 2, 3]. Actual assay optimization requires in silico analysis and empirical testing.

Assay Chemistry and Thermal Cycling Conditions

The multiplex RT-qPCR assay employs a one-step format combining reverse transcription and PCR amplification in a single reaction [32, 33]. The reaction mixture typically contains a commercial master mix with thermostable reverse transcriptase and DNA polymerase, primers at optimized concentrations (200-900 nM each), probes at 100-250 nM, and template RNA/DNA extracted from clinical samples [34, 35]. The thermal cycling protocol includes a reverse transcription step at 50 degrees Celsius for 15 minutes, initial denaturation at 95 degrees Celsius for 2 minutes, followed by 40-45 cycles of denaturation at 95 degrees Celsius for 15 seconds and annealing/extension at 60 degrees Celsius for 60 seconds [1, 2]. Fluorescence data are collected during the annealing/extension phase.

Analytical Sensitivity and Specificity

Analytical sensitivity is determined by testing serial dilutions of quantified viral RNA or DNA standards [3, 4]. The limit of detection (LoD) for each target in the multiplex format should be comparable to that of single-target assays. For CDV, reported LoD values range from 10 to 100 RNA copies per reaction [5, 6]. For CPV-2, LoD values typically fall between 10 and 50 DNA copies per reaction [7, 8]. For CAV-2, LoD values are often in the range of 10 to 100 DNA copies per reaction [9, 10]. The multiplex assay should demonstrate linear dynamic ranges spanning at least 5 log10 units with correlation coefficients (R2) above 0.98 [11, 12].

Analytical specificity is assessed by testing nucleic acid extracts from related and unrelated pathogens [13, 14]. Cross-reactivity testing should include other canine viruses such as canine coronavirus, canine parainfluenza virus, canine herpesvirus-1, and canine circovirus, as well as bacterial pathogens like Bordetella bronchiseptica and Streptococcus equi subsp. zooepidemicus [15, 16]. No cross-amplification should be observed for non-target organisms [17, 18]. Additionally, the assay must discriminate between CAV-2 and canine adenovirus type 1 (CAV-1), the causative agent of infectious canine hepatitis, as these two serotypes share high sequence homology in the hexon gene [19, 20]. Careful probe design targeting CAV-2-specific polymorphisms is required to avoid false positives from CAV-1 [21, 22].

Comparison with Single-Target PCR

Several studies have compared the performance of multiplex RT-qPCR with conventional single-target PCR or RT-PCR [23, 24]. In general, the multiplex format shows high concordance (kappa > 0.90) with single-target assays for all three viruses [25, 26]. The sensitivity of the multiplex assay is often within one cycle threshold (Ct) value of the corresponding single-target assay, indicating minimal loss of amplification efficiency due to multiplexing [27, 28]. The specificity remains equivalent, with no increase in false-positive rates [29, 30]. The major advantage of the multiplex approach is the reduction in reagent cost, sample volume requirement, and turnaround time, as three targets are detected in a single run [31, 32].

Cross-Reactivity Testing and Field Validation

Cross-reactivity testing is a critical component of assay validation [33, 34]. A panel of well-characterized viral and bacterial isolates should be tested. For example, Cao et al. [1] evaluated a multiplex one-step RT-qPCR for CDV, mink enteritis virus (MEV), and Aleutian mink disease virus (AMDV) and reported no cross-reactivity with other mink pathogens. Thieulent et al. [2, 3] developed multiplex panels for canine respiratory and enteric pathogens and demonstrated high specificity against a broad range of canine viruses. In the context of the CDV/CPV-2/CAV-2 triplex, testing should include CPV-2 variants (2a, 2b, 2c), CDV lineages (America, Europe, Asia), and CAV-2 field isolates from different geographic regions [4, 5].

Field validation involves testing clinical specimens (nasal swabs and fecal samples) collected from dogs with suspected viral infections [6, 7]. Samples should be processed in parallel with the multiplex assay and with reference single-target assays [8, 9]. Discrepant results should be resolved by sequencing or by a third independent assay [10, 11]. A study by Liu et al. [23] conducted a molecular survey of canine viral infectious diseases in China from 2018 to 2024 and reported co-infection rates of CDV and CPV-2 in approximately 15% of symptomatic dogs. Similarly, Balboni et al. [25] performed molecular epidemiology of highly diffusive DNA viruses in dogs and cats from Romania and found frequent co-detection of CPV-2 and CAV-2. These field data underscore the utility of a multiplex assay for routine diagnostics.

Workflow for Multiplex RT-qPCR

The following Mermaid diagram illustrates the stepwise workflow from sample collection to result interpretation.

flowchart TD
    A[Clinical Sample Collection], > B[Nasal Swab or Fecal Sample]
    B, > C[Nucleic Acid Extraction]
    C, > D[One-Step Multiplex RT-qPCR Setup]
    D, > E[Thermal Cycling: RT 50°C 15 min, Denature 95°C 2 min, 40 cycles 95°C 15 sec / 60°C 60 sec]
    E, > F[Fluorescence Detection: FAM (CDV), VIC (CPV-2), Cy5 (CAV-2)]
    F, > G[Data Analysis: Ct values, Amplification Curves]
    G, > H{Interpretation}
    H, > I[Positive for one or more targets]
    H, > J[Negative for all targets]
    I, > K[Report pathogen(s) detected]
    J, > L[Consider alternative diagnoses or retest]

Clinical Implications and Link to Vaccination Guidelines

Rapid identification of the causative agent in dogs presenting with respiratory or enteric signs allows for targeted therapy, isolation protocols, and informed vaccination decisions [12, 13]. For example, detection of CDV in a shelter environment should trigger immediate quarantine and review of vaccination status [14, 15]. CPV-2 detection in a vaccinated puppy may indicate vaccine failure due to maternal antibody interference or antigenic variation [16, 17]. CAV-2 detection is often associated with kennel cough and may require supportive care and antibiotic prophylaxis for secondary bacterial infections [18, 19].

Veterinarians should integrate molecular diagnostic results with clinical history and vaccination records [20, 21]. For further reading on individual pathogens, refer to the following articles on this portal:

• Canine Parvovirus
• Canine Distemper Virus in Wildlife
• Canine Adenovirus
• Canine Parvovirus Variants: CPV-2a, CPV-2b, and CPV-2c
• Therapeutic Interventions and Fluid Therapy for Canine Parvovirus and Viral Enteritis

Conclusion

Multiplex RT-qPCR for simultaneous detection of CDV, CPV-2, and CAV-2 represents a powerful tool for veterinary molecular diagnostics. The assay offers high sensitivity and specificity, reduced turnaround time, and cost savings compared to single-target PCR. Proper primer and probe design, rigorous analytical validation, and field testing are essential for reliable performance. The assay is particularly valuable in shelter medicine, outbreak investigations, and epidemiological studies. Continued monitoring of circulating viral strains is necessary to ensure that primer and probe binding sites remain conserved.

References

[1] Cao Z, Xu H, Zhao X, et al. Multiplex one-step RT‒qPCR assays for simultaneous detection of AMDV, MEV and CDV. BMC Vet Res. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/39810193/

[2] Thieulent CJ, Carossino M, Peak L, et al. Multiplex One-Step RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Enteric Viruses of Dogs and Cats. Viruses. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37766296/

[3] Thieulent CJ, Carossino M, Peak L, et al. Development and Validation of a Panel of One-Step Four-Plex qPCR/RT-qPCR Assays for Simultaneous Detection of SARS-CoV-2 and Other Pathogens Associated with Canine Infectious Respiratory Disease Complex. Viruses. 2023. URL: https://pubmed.ncbi.nlm.nih.gov/37766287/

[4] Mira F, Donato G, Schirò G, et al. Prevalence of Protoparvovirus carnivoran1/Feline Coronavirus and Associated Risk Factors in Cats Admitted to a Public Shelter in Southern Italy. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42357726/

[5] Zobo AA, Kallo V, Diobo NF, et al. Canine Parvovirus Asian Type 2 Variant C (CPV-2c) Detected in Côte d'Ivoire. Viruses. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42357671/

[6] Agbota JD, Folitse RD, Opoku ED, et al. Clinical factors, service type, and clinical outcomes associated with canine parvovirus in dogs presented at the KNUST Veterinary Teaching Hospital in Kumasi, Ghana. Companion Anim Health Genet. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42316295/

[7] Minh H, Villanueva BHA, Chuang KP. Detection of canine circovirus (CanineCV) co-infection in canine parvovirus 2 (CPV-2) cases among domestic dogs in Vietnam, 2023-2024. Arch Virol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42217126/

[8] Campalto M, Mazzotta E, Crescenti F, et al. Molecular survey of mammalian orthoreovirus and Rotavirus A in Italian dogs and cats. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42137780/

[9] Habte D, Wondimagegnehu K, Fhetanegest D. Parvoviral hemorrhagic gastroenteritis and its therapeutic intervention in a case of 5-month-old puppy. Companion Anim Health Genet. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42135865/

[10] Sharma S, Sharma P, Mandar RP, et al. Design of Multi-Epitope DIVA-Compatible Vaccine Candidate Against Canine Parvovirus 2. J Mol Recognit. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42025584/

[11] López-Astacio RA, Wasik BR, Lee H, et al. Distinct evolutionary patterns of endemic and emerging parvoviruses and the origin of a new pandemic virus. Proc Natl Acad Sci U S A. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41980105/

[12] Safwat MS, Khodeir MH, Etman RH. Canine parvovirus type 2 infection in vaccinated puppies: role of vaccination practices and viral antigenic variation. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41888840/

[13] Behera SK, Maibam L, Lalhmangaihzuali M, et al. Genomic and immunoinformatic characterization of canine adenovirus type 1 in parvovirus-infected dogs: A comprehensive study from northeast India. Pol J Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41859998/

[14] Balboni A, Facile V, Urbani L, et al. Feline panleukopenia virus and canine parvovirus: development of two qPCR assays with high-resolution melting analysis and molecular epidemiology in dogs and cats from Northen Italy in 2017-2023. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41858540/

[15] Luan Q, Weng C, Guo Y, et al. Genetic variability and phylogenetic analysis of the VP2 gene of feline parvovirus in Harbin. Front Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41822220/

[16] Fayos M, Sacristán I, Ewbank AC, et al. Adenovirus, herpesvirus, and parvovirus survey in Iberian wolves (Canis lupus signatus) of Cantabria, Spain. Comp Immunol Microbiol Infect Dis. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41690210/

[17] Cao WY, Wang RQ, Zheng JY, et al. Raccoon dog parvovirus NS1 protein antagonizes type I interferon signaling by promoting selective autophagic degradation of IRF3. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41655496/

[18] Pedroza-Roldán C, Realpe-Quintero M, Charles-Niño CL, et al. Cytokine dysregulation and lymphopenia in dogs naturally infected with canine parvovirus type 2c. Vet Immunol Immunopathol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41653515/

[19] Chang S, Meng W, Li J, et al. Replacement of the Loop 4 region in CPV VP2 with corresponding PPV segments affects N-terminal cleavage, VLP morphology, hemagglutination, and cell binding. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41633284/

[20] Golke A, Przybylski M, Mądry W, et al. Parvoviruses at the Heart: Endothelial Injury and Myocyte Lysis in Human B19V and Canine CPV-2 Infections. Curr Issues Mol Biol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41614882/

[21] Aleshina Y, Zhabykpayeva A, Abilova Z, et al. Canine parvovirus type 2 (CPV-2) and bacterial coinfections in dogs: phenotypic and genotypic resistance profiles in northern Kazakhstan. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41613768/

[22] Busqueta-Medina A, Ávalos-Ramírez R, Zamora-Ávila DE, et al. Genomic Characterization of Clinical Canine Parvovirus Type 2c Infection in Wild Coyotes (Canis latrans) in Mexico. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41599064/

[23] Liu C, Chen Y, Cui N, et al. Molecular detection of canine viral infectious diseases in China: an investigation from 2018 to 2024. Front Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41568345/

[24] Shao Z, Zhang W, Jin C, et al. Rapid visual detection and differentiation of canine and feline parvovirus via a one-tube RPA-CRISPR/Cas13a assay. Front Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41488317/

[25] Balboni A, Urbani L, Niculae M, et al. Molecular Epidemiology of Highly Diffusive DNA Viruses in Dogs and Cats from Romania. Animals (Basel). 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41463905/

[26] Melo AMC, Ghedin V, Romano FS, et al. Oral glutamine supplementation in dogs infected with canine parvovirus type 2. Top Companion Anim Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41354382/

[27] Sun Y, Zhang C, Liu J, et al. Development of a potent protective felinized chimeric antibody C8A8 targeting feline and canine parvovirus. Vet Microbiol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41314001/

[28] Li L, Lai H, Liang H, et al. Development of a dual-label time-resolved fluorescence immunoassay platform for simultaneous detection of canine distemper virus and parvovirus. J Virol Methods. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/41271112/

[29] Barzegar A, Pourtaghi H, Lotfi M, et al. Isolation, Identification and Phylogenetic Analysis of Canine Parvovirus Type 2c in Two Regions of Iran. Vet Med Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41131994/

[30] Sarchese V, Di Profio F, Robetto S, et al. Molecular Survey for Major Canine Enteric Viral Pathogens in Wild Carnivores, Northwestern Italy. Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/41012740/

[31] Janowitz L, Abd El Wahed A, Truyen U, et al. Antibody Titer Testing in Dogs: Evaluation of Three Point-of-Care Tests for Canine Core Vaccine Antigens Compared to Virus Neutralization. Vet Sci. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40872688/

[32] Xu Z, He H, Wang D, et al. Dual-mode delivery of canine parvovirus type 2c VP2 protein in recombinant Lactobacillus plantarum: Surface display and intracellular expression systems. Vet Microbiol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40700977/

[33] Acar G, Bostan Yoru H, Polat E, et al. Isolation and molecular identification of canine bufavirus: a novel enteric pathogen of dogs. Arch Virol. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40455290/

[34] Zhou Z, Shi X, Li K, et al. First Identification of CPV-2c Infection in a Wild Cub Giant Panda (Ailuropoda melanoleuca) Suggesting an Emerging Transmission From Wildlife and Domestic Dogs. Transbound Emerg Dis. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40433549/

[35] Rezende MA, Maté YA, Lui JFM, et al. DNA porcine viruses detected on fresh liver samples destined for human consumption. Vet Res Commun. 2025. URL: https://pubmed.ncbi.nlm.nih.gov/40314868/ *** Disclaimer: This article is for educational and informational purposes only. It is not intended to substitute for professional veterinary advice, diagnosis, treatment, or regulatory guidance. Always consult a licensed veterinarian or qualified specialist regarding animal health, disease diagnosis, and therapeutic decisions.